Home/Current Allergy and Clinical Immunology/Article Record
Peer-Reviewed Article December 31, 2008

H 1 ANTIHISTAMINES IN ALLERGIC DISEASE

Are you an author of this work?Link to your sovereign AfriScholar profile
Published in: Current Allergy and Clinical Immunology
Publisher: Allergy Society of South Africa • South Africa • 1609-3607

Abstract

Histamine (one of the key mediators released from mast cells and basophils), plays a major role in the pathophysiology of allergic diseases, including rhinitis, urticaria, asthma and anaphylaxis. Histamine exerts its effects through its interaction with one of four distinct receptors (H1, H2, H3, H4). In allergic disease, it is the H1 antihistamines which are of primary benefit, although H2 antihistamines may also play a therapeutic role. H1 antihistamines remain first-line medications for the treatment of allergic rhinoconjunctivitis and urticaria. Second-generation antihistamines are preferred to their predecessors because of better benefit-to-risk ratios. The newer antihistamines are not only more potent, but also have anti-allergic and anti-inflammatory properties. Although they are more expensive than the traditional antihistamines, the cost is substantially offset by their superior efficacy and safety profile when used in recommended dosages.

Download Full Text PDFView at PublisherCrossref XML

Verified Citation Velocity

Recorded scholarly citations in African and international peer-reviewed literature

9
Total Citations

Citations are continuously tracked and harvested across continental OJS endpoints and OpenAlex feeds.